Short answer
West Pharmaceutical Services (WST) filed its Q2 2026 10-Q quarterly report on Jul 23, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $872M (up 13.8% year over year) with net income of $154M.
Q2 2026 key financials · XBRL
- Revenue
- $872M
- +13.8% YoY · +3.2% QoQ
- Net income
- $154M
- +16.8% YoY · +11.0% QoQ
- Operating margin
- 20.5%
- Gross margin
- 37.7%
- EPS (diluted)
- $2.15
- +18.1% YoY · +12.0% QoQ
Source: XBRL data from the West Pharmaceutical Services (WST) Q2 2026 10-Q on SEC EDGAR. USD.
West Pharmaceutical Services Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered cybersecurity risk: May 2026 attack exfiltrated data and encrypted systems
- Operational disruption: Global systems taken offline, temporarily interrupting operations before full recovery
- Regulatory exposure: Privacy noncompliance could cause financial losses and reputational damage
- Cybersecurity costs: Insurance limits may not cover damages or fines exceeding policy limits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other West Pharmaceutical Services quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.